GlassScriptPhysician profile
Fabio Cappuccini
NPI 1255346763
$313,050.63
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37K · 2020: $25K · 2021: $66K · 2022: $103K · 2023: $61K · 2024: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $54K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $12K · Travel and Lodging: $12K · Food and Beverage: $1,312 · Consulting Fee: $1,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $54,260.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $12,428.75 |
| Travel and Lodging | $12,231.55 |
| Food and Beverage | $1,311.51 |
| Consulting Fee | $1,018.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $144,234.13 | 2019-2023 | Jemperli, Zejula |
| Eisai INC. | $89,389.59 | 2020-2024 | |
| Tesaro, INC. | $36,483.17 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $26,735.41 | 2020-2023 | Lynparza |
| Merck Sharp & Dohme LLC | $15,234.03 | 2019-2024 | Keytruda, Lynparza |
| Clovis Oncology, INC. | $586.71 | 2020-2022 | |
| Biom'Up Sa | $148.87 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $105.43 | 2019 | |
| Immunogen, INC. | $74.05 | 2023 | Elahere |
| Myriad Genetic Laboratories, INC. | $59.24 | 2021-2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fabio Cappuccini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.